Amarillo Biosciences, Inc. Will Receive Payments
AMARILLO, Texas, Oct. 23 /PRNewswire/ -- Amarillo Biosciences, Inc.
(OTC Bulletin Board: AMAR) announces the company's supply agreement with
Natrol, Inc. (Nasdaq: NTOL) will result in Natrol's "Dry Mouth Relief" brand
being sold in over 2,000 Eckerd pharmacies starting October, 2001. The
Company will receive payments on the sale of Natrol's "Dry Mouth Relief."
"Dry Mouth Relief," a patented dietary supplement, is the trade name for
pharmaceutical grade anhydrous crystalline maltose, which has been found to
relieve complaints of dry mouth, enhance salivary function, and promote oral
comfort. Amarillo Biosciences, Inc. is the exclusive supplier of
pharmaceutical grade anhydrous crystalline maltose to Natrol, Inc.
Dr. Joseph M. Cummins, President and CEO of Amarillo Biosciences, Inc.
said, "We are very pleased with 'Dry Mouth Relief' being sold in such
high-traffic, recognized pharmacies. Researchers estimate that at least
20% of the population over 50 years of age, as many as 15 million persons,
suffer from persistent complaints of dry mouth. That number could go higher
than 25 - 40 million persons if you include people in the US who suffer from
autoimmune diseases and take prescription medications that cause dry mouth."
Dr. Cummins concluded, "Our proven ability to develop innovative, new
products in close cooperation with our customers will enable us to continue to
take advantage of the many growth opportunities in the biotechnology market.
We believe this market is poised for significant growth."
About Amarillo Biosciences, Inc.
Amarillo Biosciences, Inc. is a pioneer in the research of low dose
orally-administered interferon alpha as a treatment for a variety of
conditions including Sjogren's syndrome, fibromyalgia syndrome, Behcet's
disease, hepatitis B and C, and opportunistic infections in patients who are
HIV positive. Additional information is available on the Amarillo
Biosciences, Inc. web site at http://www.amarbio.com .
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including uncertainties related to product
development, uncertainties related to the need for regulatory and other
government approvals, dependence on proprietary technology, uncertainty of
market acceptance of oral interferon alpha or the Company's other product
candidates and other risks detailed from time to time in the Company's filings
with the Securities and Exchange Commission. In particular, see "Item 1.
Description of Business" of the Company's Form 10-KSB for the year ended
December 31, 2000.
SOURCE Amarillo Biosciences, Inc.
 back to top
Related links:
http://www.amarbio.com
Company News On-Call:
http://www.prnewswire.com/comp/118055.html
CONTACT:
Dr. Joseph M. Cummins, President & CEO of
Amarillo Biosciences, Inc., +1-806-376-1741, ext. 13; or Jim
Drewitz, Investor Relations, +1-972-355-6070, for Amarillo
Biosciences, Inc.
|
